Clarametyx Biosciences Expands Team Expertise to Accelerate Pipeline Momentum
Clarametyx Biosciences Announces $33M Series A Financing
COLUMBUS, Ohio--(BUSINESS WIRE)--Clarametyx Biosciences, Inc. (“Clarametyx”), a biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections associated with biofilms, today announced positive initial safety data from the Phase 1a portion of its clinical development program for CMTX-101, a novel immune-enabling antibody therapy designed to treat serious bacterial infections, with no safety concerns identified.
COLUMBUS, Ohio--(BUSINESS WIRE)--Clarametyx Biosciences Inc. (“Clarametyx”), a clinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, today announced the appointment of Dr. Jeffrey Almond to the company’s scientific advisory board (SAB). The company also announced the departure of Dr. Elyse Seltzer, who is stepping down to take a consultant role as a Senior Therapeutic Subject Matter Expert to the federal public health agency BARDA (Biomedical Advanced Research and Development Authority).
Clarametyx Biosciences has commenced the Phase Ia clinical trial of its immune-enabling antibody therapy, CMTX-101, to potentially treat community-acquired bacterial pneumonia (CABP).
Clarametyx Initiates Phase 1 Study of Immune-enabling Antibody Therapy CMTX-101 Against Community-acquired Bacterial Pneumonia
COLUMBUS, Ohio--(BUSINESS WIRE)--Clarametyx Biosciences Inc. (“Clarametyx”), a biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections associated with biofilms, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application to initiate a first-in-human Phase 1 safety study followed by a Phase 1b trial of CMTX-101, a novel immune-enabling antibody therapy.
COLUMBUS, Ohio--(BUSINESS WIRE)--Clarametyx Biosciences Inc. (“Clarametyx”), a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections associated with biofilms, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to accelerating antibacterial research and development, has awarded the company an additional $3.89 million in option funding. The grant is directed toward accelerated development of CMTX-101, a novel anti-biofilm therapy with a first targeted indication for moderate-to-severe pneumonia.
COLUMBUS, Ohio--(BUSINESS WIRE)--Clarametyx Biosciences Inc., (“Clarametyx”) a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, today announced the publication of a new study in eBioMedicine. The study demonstrates the potential impact of addressing resistant or recalcitrant infections by targeting the universal stabilizing structure of bacterial biofilms, a protective layer over bacteria that is present in as much as 80 percent of bacterial infections and contributes to persistent infections, inflammation, and resistance to therapeutic interventions.